| Literature DB >> 26297110 |
Sun Young Lee1, Vincent Cheng, Damien Rodger, Narsing Rao.
Abstract
BACKGROUND: Ocular syphilis is reemerging as an important cause of uveitis in the new era of common co-infection with HIV. This study will reveal the clinical and laboratory characteristics in the group of individuals co-infected with ocular syphilis and HIV compared with HIV-negative individuals. In this retrospective observational case series, medical records of patients diagnosed with ocular syphilis with serologic support from 2008 to 2014 were reviewed. Ocular and systemic manifestation and laboratory profiles were reviewed.Entities:
Year: 2015 PMID: 26297110 PMCID: PMC4546070 DOI: 10.1186/s12348-015-0056-x
Source DB: PubMed Journal: J Ophthalmic Inflamm Infect ISSN: 1869-5760
Fig. 1Newly diagnosed ocular syphilis patients by year
Clinical findings of ocular syphilis in HIV-positive and HIV-negative patients
| Initial VA | Type of uveitis | Treatment | Final VA | FU duration | |
|---|---|---|---|---|---|
| 1 | OD 20/50 | Posterior uveitis | IV PCN × 14 days | OD 20/40 | 8 years |
| OS 20/30 | Posterior uveitis | OS 20/40 | |||
| 2 | OD LP | Panuveitis | IV PCN × 14 days | OD 20/25 | 3 years |
| OS 20/30 | Panuveitis | OS 20/80 | |||
| 3 | OD 20/30 | Panuveitis | IV PCN × 14 days | OD 20/70 | 2 years |
| OS 20/40 | Panuveitis | IM PCN × 3 weeks | OS 20/40 | ||
| 4 | OD 20/20 | None | IV PCN × 14 days | OD 20/25 | 10 months |
| OS 20/200 | Panuveitis | IM PCN × 3 weeks | OS 4 ft/200 | ||
| 5 | OD 20/25 | Anterior uveitis | IV PCN × 10 days | OD 20/30 | 1 months |
| OS 20/40 | Panuveitis | OS 20/40 | |||
| 6 | OD 20/150 | Panuveitis | IV PCN × 14 days | OD 20/25 | 4 months |
| OS HM | Panuveitis | IM PCN × 3 weeks | OS 20/80 | ||
| 7 | OD 20/25 | Papillitis | IV ceftriaxone × 14 days | OD 20/40 | 4 months |
| OS 20/20 | Papillitis | Doxycycline po × 21 days | OS 20/40 | ||
| 8 | OD 20/30 | Anterior uveitis | IV PCN × 14 days | OD 20/40 | 4 months |
| OS 20/30 | Anterior uveitis | OS 20/25 | |||
| 9 | OD 20/30 | Panuveitis | IV PCN × 14 days | OD 20/30 | 1 months |
| OS 20/30 | Panuveitis | OS 20/40 | |||
| 10 | OD 20/150 | Panuveitis | IV PCN × 14 days | OD 20/70 | 1 months |
| OS HM | Panuveitis | OS 8/200 | |||
| 11 | OD 20/400 | Posterior uveitis | IV PCN × 14 days | OD 20/150 | 7 months |
| OS 20/200 | Posterior uveitis | OS 20/150 | |||
| 12 | OD 20/25 | Posterior uveitis | IV PCN incomplete | OD NA | Lost to FU |
| OS HM | Posterior uveitis, CN III, VII palsy | OS NA | |||
| 13 | OD prosthesis | Anterior uveitis | IV PCN × 12 days | OD prosthesis | 1 months |
| OS 20/25 | OS 20/40 | ||||
| 14 | OD 20/30 | None | IV PCN × 10 days | OD 20/25 | 3 years |
| OS 8 ft/200 | Panuveitis | OS 20/400 | |||
| 15 | OD CF | Posterior uveitis | Lost to FU | OD NA | Lost to FU |
| OS HM | Posterior uveitis | OS NA | |||
| 16 | OD NLP | Pale disc | IV PCN × 14 days | OD NLP | 12 months |
| OS 20/60 | Papillitis | OS 20/40 |
VA visual acuity, FU follow-up, LP light perception, HM hand motion, NLP no light perception, PCN, penicillin
Fig. 2Serum RPR titers at diagnosis by HIV status
Syphilis serology test of serum and CSF in HIV-positive and HIV-negative patients
| Age/gender/race | HIV | Serology | CSF Pa; Cb | CD4c | HIV-1 viral loadd | Last RPR | |
|---|---|---|---|---|---|---|---|
| 1 | 40/M/B | + | RPR+ (1:64); FTA-ABS+ | NR | 535 | 24,561 | NR (5 years) |
| 2 | 43/M/H | + | RPR+ (1:1024); FTA-ABS+ | FTA-ABS+ | 137 | >5,000,000 | 1:64 (15 months) |
| 3 | 20/M/H | + | RPR+ (1:2048); FTA-ABS+ | FTA-ABS+ | 376 | 189,089 | 1:16 (10 months) |
| 4 | 28/M/W | + | RPR+ (1:16,384); FTA-ABS+ | VDRL+ | 127 | 496,559 | 1:16 (1 year) |
| 5 | 27/M/H | + | RPR+ (1:512); FTA-ABS+ | VDRL+ | 134 | NA | NA |
| 6 | 48/M/W | + | RPR+ (1:64); FTA-ABS+ | FTA-ABS+ | 124 | 224,685 | NA |
| 7 | 49/M/H | + | RPR+ (1:64); FTA-ABS+ | NR | NA | NA | 1:8 (4 months) |
| 8 | 25/M/B | + | RPR+ (1:1024); FTA-ABS+ | NR | 134 | NA | NA |
| 9 | 46/M/H | + | RPR+ (1:1024); FTA-ABS+ | FTA-ABS+ | 371 | 117,779 | 1:64 (1 month) |
| 10 | 50/M/H | + | RPR+ (1:256); FTA-ABS+ | NA | 201 | NA | NA |
| 11 | 59/M/H | − | RPR+ (1:2); FTA-ABS+ | NR | 1:2 (1 month) | ||
| 12 | 63/M/H | − | RPR+ (1:2); FTA-ABS+ | NR | NA | ||
| 13 | 51/M/B | − | RPR+ (1:2); FTA-ABS+ | NR | NA | ||
| 14 | 52/M/H | − | RPR+ (1:2); FTA-ABS+ | NR | NR | ||
| 15 | 58/M/B | − | RPR+ (1:8); FTA-ABS+ | NR | 1:8 (6 months) | ||
| 16 | 55/M/O | − | RPR+ (1:2048); FTA-ABS+ | VDRL+ | 1:128 (1 year) |
B black, W white, H Hispanic, M male, RPR rapid plasma reagin, FTA-ABS fluorescent treponemal antibody absorption, NR non-reactive, NA not available
aCSF protein mg/dl
bCSF WBC count cell/ml
ccell/ml
dcopies/ml